I-Mab (Nasdaq: IMAB), a China-based clinical-stage biopharmaceutical company, announced on Thursday that it has named Richard Yeh as its new chief operating officer and Dr John Hayslip as its new chief medical officer.

Yeh has over 25 years of experience in senior leadership positions with biopharmaceutical companies and prominent Wall Street firms. He has served as chief financial officer and head of Strategic Operations at Abbisko Therapeutics (HKEX: 2256), a series of leadership positions including chief financial officer of CStone Pharmaceuticals (HKEX: 2616), managing director and business unit leader of Asia Pacific healthcare equity research at Goldman Sachs (Asia), and head of China and regional healthcare research team at Citigroup Capital Markets Asia. He has experience in equity research in the United States biotechnology sector at major companies including Citigroup and Bank of America Securities. He has served in the global strategic marketing group at Wyeth Pharmaceuticals and conducted drug discovery research at Amgen.

Dr Hayslip has served as vice president of Clinical Development at Nektar Therapeutics (Nasdaq: NKTR). He has also led development activities for multiple therapies while at AbbVie Oncology. He has served as an accomplished researcher and physician at the University of Kentucky's Markey Cancer Center. He has also worked as the chief for Hematology and Bone Marrow Transplant and as director of Clinical Research and Data Management at the Markey Cancer Center.